State of New Jersey Common Pension Fund D Has $1.53 Million Stake in TG Therapeutics, Inc. $TGTX

State of New Jersey Common Pension Fund D lessened its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX) by 30.4% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 51,448 shares of the biopharmaceutical company’s stock after selling 22,485 shares during the period. State of New Jersey Common Pension Fund D’s holdings in TG Therapeutics were worth $1,534,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Congress Asset Management Co. bought a new position in TG Therapeutics in the 4th quarter valued at $57,307,000. Nordea Investment Management AB acquired a new position in TG Therapeutics during the 4th quarter valued at about $2,356,000. Penn Capital Management Company LLC boosted its stake in TG Therapeutics by 17.6% in the third quarter. Penn Capital Management Company LLC now owns 521,260 shares of the biopharmaceutical company’s stock valued at $18,877,000 after acquiring an additional 77,895 shares during the last quarter. Public Sector Pension Investment Board boosted its position in shares of TG Therapeutics by 14.5% in the 3rd quarter. Public Sector Pension Investment Board now owns 529,271 shares of the biopharmaceutical company’s stock worth $19,120,000 after purchasing an additional 66,911 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its holdings in TG Therapeutics by 56.1% during the third quarter. JPMorgan Chase & Co. now owns 227,934 shares of the biopharmaceutical company’s stock worth $8,234,000 after buying an additional 81,907 shares during the last quarter. Institutional investors own 58.58% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on TGTX. HC Wainwright lifted their price target on shares of TG Therapeutics from $60.00 to $70.00 and gave the stock a “buy” rating in a research report on Wednesday. Zacks Research downgraded TG Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Friday, May 1st. Cantor Fitzgerald reissued an “overweight” rating on shares of TG Therapeutics in a research report on Wednesday, January 14th. The Goldman Sachs Group upped their target price on TG Therapeutics from $37.00 to $39.00 and gave the company a “neutral” rating in a research report on Thursday, January 15th. Finally, Weiss Ratings raised shares of TG Therapeutics from a “hold (c)” rating to a “hold (c+)” rating in a research report on Friday, May 1st. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $52.50.

Key TG Therapeutics News

Here are the key news stories impacting TG Therapeutics this week:

• Positive Sentiment: HC Wainwright boosted its EPS forecasts for TG Therapeutics across 2026 and the out-years, signaling stronger expected profitability and reinforcing its Buy rating and $70 price target.
• Positive Sentiment: The company’s Q1 results showed strong revenue growth and improving BRIUMVI sales, and management raised its revenue outlook, which is helping offset the EPS miss and support the stock.
• Neutral Sentiment: HC Wainwright’s raised long-term estimates for TG Therapeutics through FY2030 suggest confidence in the company’s growth trajectory, but these projections are farther out and less likely to drive near-term trading on their own.

TG Therapeutics Price Performance

TG Therapeutics stock opened at $42.86 on Monday. The stock has a market capitalization of $6.56 billion, a P/E ratio of 14.99 and a beta of 1.68. The company has a debt-to-equity ratio of 1.28, a quick ratio of 5.12 and a current ratio of 5.81. TG Therapeutics, Inc. has a 52 week low of $25.28 and a 52 week high of $44.65. The stock has a fifty day moving average of $32.72 and a 200-day moving average of $31.60.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.11). TG Therapeutics had a net margin of 65.95% and a return on equity of 88.73%. The company had revenue of $204.92 million during the quarter, compared to analyst estimates of $200.33 million. During the same quarter in the previous year, the business posted $0.03 earnings per share. The company’s revenue for the quarter was up 69.5% on a year-over-year basis. On average, sell-side analysts expect that TG Therapeutics, Inc. will post 1.3 earnings per share for the current fiscal year.

About TG Therapeutics

TG Therapeutics, Inc is a clinical?stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small?molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.